Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.

Literature DB >> 15710996

Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.

R Sprenger, M Sagmeister, F Offner.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2005 PMID： 15710996 PMCID： PMC1774409 DOI： 10.1136/gut.2004.049940

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

× No keyword cloud information.

13 in total

1. Ulcerative colitis associated with interferon treatment for chronic hepatitis C.

Authors: C Mavrogiannis; I S Papanikolaou; I S Elefsiniotis; D I Psilopoulos; A Karameris; G Karvountzis
Journal: J Hepatol Date: 2001-06 Impact factor: 25.083

Review 2. [A case of ulcerative colitis along with characteristic features on computed tomography (CT), developed by the treatment with interferon for chronic hepatitis C].

Authors: T Niki; K Nishida; Y Honsako; Y Matsumura; H Ueno; T Fujimi; T Sashikata
Journal: Nihon Shokakibyo Gakkai Zasshi Date: 2001-04

Review 3. [A case of acute phase ulcerative colitis like colitis developed by the interferon-beta therapy for chronic hepatitis C].

Authors: Teruhito Awakawa; Sae Hirohashi; Kimiko Hasegawa; Hiroyuki Tsukuda; Yumiko Ibayashi; Toshimitsu Hirane; Takeaki Kobayashi; Eiichi Bekki; Kohzoh Imai
Journal: Nihon Shokakibyo Gakkai Zasshi Date: 2003-06

4. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis.

Authors: S M Madsen; P Schlichting; B Davidsen; O H Nielsen; B Federspiel; P Riis; P Munkholm
Journal: Am J Gastroenterol Date: 2001-06 Impact factor: 10.864

5. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.

Authors: S Nikolaus; P Rutgeerts; R Fedorak; A H Steinhart; G E Wild; D Theuer; J Möhrle; S Schreiber
Journal: Gut Date: 2003-09 Impact factor: 23.059

6. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial.

Authors: E Musch; T Andus; M Malek
Journal: Aliment Pharmacol Ther Date: 2002-07 Impact factor: 8.171

7. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors: Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808

8. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.

Authors: H Tilg; H Vogelsang; O Ludwiczek; H Lochs; A Kaser; J-F Colombel; H Ulmer; P Rutgeerts; S Krüger; A Cortot; G D'Haens; M Harrer; C Gasche; F Wrba; I Kuhn; W Reinisch
Journal: Gut Date: 2003-12 Impact factor: 23.059

9. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.

Authors: Seema Baid; Nina Tolkoff-Rubin; Susan Saidman; Raymond Chung; Winfred W Williams; Hugh Auchincloss; Robert B Colvin; Francis L Delmonico; A Benedict Cosimi; Manuel Pascual
Journal: Am J Transplant Date: 2003-01 Impact factor: 8.086

10. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease.

Authors: C Gasché; W Reinisch; H Vogelsang; R Pötzi; E Markis; M Micksche; H P Wirth; A Gangl; H Lochs
Journal: Dig Dis Sci Date: 1995-04 Impact factor: 3.199

20 in total

1. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin.

Authors: T Watanabe; M Inoue; K Harada; N Homma; M Uchida; N Ogata; R Funada; K Hasegawa; K Soga; K Shibasaki
Journal: Gut Date: 2006-11 Impact factor: 23.059

2. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors: Yvette Leung; Stefan J Urbanski; Lynn Schindel; Robert P Myers
Journal: Can J Gastroenterol Date: 2006-10 Impact factor: 3.522

3. Interferon-α increases monocyte migration via platelet-monocyte interaction in murine intestinal microvessels.

Authors: M Higashiyama; R Hokari; C Kurihara; T Ueda; M Nakamura; S Komoto; Y Okada; C Watanabe; A Kawaguchi; S Nagao; S Miura
Journal: Clin Exp Immunol Date: 2010-08-19 Impact factor: 4.330

4. Peptidoglycan recognition proteins protect mice from experimental colitis by promoting normal gut flora and preventing induction of interferon-gamma.

Authors: Sukumar Saha; Xuefang Jing; Shin Yong Park; Shiyong Wang; Xinna Li; Dipika Gupta; Roman Dziarski
Journal: Cell Host Microbe Date: 2010-08-19 Impact factor: 21.023

5. Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis.

Authors: Jay Luther; Stephanie Y Owyang; Tomomi Takeuchi; Tyler S Cole; Min Zhang; Maochang Liu; John Erb-Downward; Joel H Rubenstein; Chun-Chia Chen; Anna V Pierzchala; Jose A Paul; John Y Kao
Journal: Gut Date: 2011-04-06 Impact factor: 23.059